-
Chronic Kidney Disease (CKD) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Select optionsGrowth of the Prevalence CKD population will contribute to increasing sales in the CKD therapy market over our forecast period. An estimated annual growth rate of 0.4% in the Prevalent CKD population across the major pharmaceutical markets will contribute to increasing CKD therapy sales. In 2019, there were approximately 94 million prevalent cases of CKD in the major markets; we expect the number of cases will exceed 2.08 million in 2032 owing to changes in population demographics and increasing cases of CKD associated conditions such as anemia, hyperphosphatemia, secondary hyperthyroidism, diabetes kidney disease and cardiovascular patients group.
The continuous involvement of supportive treatments including renal replacement therapies for the management of dialysis dependent CKD patients will contribute to the the overall growth of the CKD therapy market. We forecast that total sales of the total current RRTs market will reach more than $13 billion by 2032.
-
Central Precocious Puberty | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Select optionsGrowth of the diagnosed CPP population will contribute to increasing sales in the CPP therapy market over our forecast period. An estimated annual growth rate of 0.12% in the diagnosed CPP population across the major pharmaceutical markets will contribute to increasing CPP therapy sales. In 2022, there were approximately xx diagnosed cases of CPP in the major markets; we expect the number of cases will exceed xx in 2032 owing to changes in population demographics and increasing awareness related to this rare disease.Strong Uptake of the 6-months Leuprolide acetate (Fensolvi) will be driven by the need for an alternative therapy for 3-months depot Leuprolide acetate and will contribute to the growth of the CPP market. We expect leuprolide acetate to be preferentially prescribed to patients. However, as physicians become more familiar with the agent, we expect Fensolvi to gain more patient share. The drug is forecasted to earn sales of $xx million in 2032. -
Anti-Neutralizing Antibodies (NAbs) Gene Therapies-Pipeline Analytics 2022
$2,700.00 – $8,100.00Select optionsAnti-Neutralizing Antibodies (NAbs) Gene Therapies report covers the Anti-Neutralizing Antibodies (NAbs) Gene Therapies market opportunity providing Key Competitive Analysis, 20+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports covers pipeline product analysis by stage of development, competitive landscape by phases, companies, therapy area and indication by phases. NAbs inhibitor’s reports add a value in terms of providing the description of clinical stage product with respect to their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers and challenges.
-
Adult Acute Lymphoblastic Leukemia (aALL) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Select optionsAbout 60% of ALL adult patients relapse or are refractory to first-line therapy and a high unmet need continues to exist. CD19 CAR T candidate with compelling activity and safety profile and has the potential to change the standard of care as a curative therapy for r / r ALL. Sales of emerging therapies to treat adult Acute Lymphoblastic Leukemia (aALL) in the countries under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will experience high growth over the 2022-2032 study period, adding an estimated value to a total more than $1 billion market by 2032
-
Acute Myeloid Leukemia (AML) -The Changing Landscape of Treatment in AML, Executive Deck 2022
$5,000.00 – $25,000.00Select optionsAcute myelogenous leukemia (AML) Disease Landscape provides comprehensive market intelligence with epidemiology, keen insight into current treatment paradigms, in-depth pipeline coverage ( ~ 500 unique industry-sponsored studies) and clinical trial landscape supported by detailed recent results from ASH 2022, ASCO 2022 and EHA 2022. The drugs are further classified according to the class of therapies: antibody drug conjugates, bispecific antibodies, tri-specific and monoclonal antibodies, CAR-T therapies & T cells therapies, vaccines, small molecules and others.
-
Acute Kidney Injury (AKI) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Select optionsGrowth of the incidence AKI population will contribute to increasing sales in the AKI therapy market over our forecast period. An estimated annual growth rate of 2.68% in the diagnosed incident AKI population across the major pharmaceutical markets will contribute to increasing AKI therapy sales. In 2019, there were approximately 1.95 million diagnosed cases of AKI in the major markets; we expect the number of cases will exceed 2 million in 2032 owing to changes in population demographics and increasing cases of AKI associated conditions such as sepsis-AKI, Cardiac surgery-associated AKI and others.
The continuous involvement of supportive treatments including renal replacement therapies for the management of AKI patients will contribute to the the overall growth of the AKI therapy market. We forecast that total sales of the total care market will reach $XX billion by 2032.
Call us today: +1 (304) 470-2225
English
You can use WPML or Polylang and their language switchers in this area.
Report Store
Home » Report Store
